Weight loss drugs scrapped

Written byEdyta Zielinska

| 1 min read

Listen with Speechify

0:00

1:00

Sanofi-Aventis announced this week that it would discontinue clinical trials of its anti-obesity drug, Acomplia. The decision followed similar moves by Pfizer and Merck, who also recently abandoned development of similar weight loss drugs. Why is everyone jumping ship? The drugs all target the cannabinoid receptor CB1 -- also the target receptor for marijuana - in order to suppress appetite (read how Acomplia's mechanism of action compares with other diet drugs linkurl:here).;https://www.the-scientist.com/2008/6/1/40/100/ However, the drugs have been under mounting scrutiny by regulatory entities in the US and Europe for increasing the risk of depression and suicidal thoughts. Acomplia has been sold in Europe since 2006, but last month the company stopped marketing the drug there after the EMEA -- Europe's version of the FDA -- said the risks to patients outweighed the benefits, according to the linkurl:__Wall Street Journal.__;https://blogs.wsj.com/health/2008/11/06/pfizer-sanofi-aventis-abandon-obesity-drugs/ In a linkurl:statement;https://www.the-scientist.com/2008/6/1/40/100/ released this week, Pfizer said that its decision to stop development was based on "changing regulatory perspectives on the risk/benefit profile of the CB1 class," of drugs. The FDA has never granted approval to any diet drugs in this class.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member?

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Edyta Zielinska
Edyta Zielinska was a senior editor at The Scientist from 2007 to 2013, where she worked closely with scientific illustrators to develop accompanying graphics to illuminate complex concepts.
View Full Profile